The clinical potential of radiopharmaceuticals is huge and with continued multi-billion-dollar investments from pharmaceutical giants such as Novartis, AstraZeneca, BMS and Eli Lilly, advancing your radiopharmaceutical manufacturing processes to keep up with the pace of innovation and ensure trials can progress is crucial.

The 2nd Targeted Radiopharmaceuticals Supply Chain and Manufacturing summit returns as the only industry driven forum dedicated to advancing your radiopharmaceutical production to build reliable supply of products and accelerate trials.

Discover how to streamline your production capabilities and create a stringent supply chain network through uncovering key topics such as, isotope production, radiolabelling, quality control, regulatory considerations and supply network logistics.

Uniting 80+ of the leading C-suite and senior decision-makers in the radiopharmaceutical CMC, regulatory, QC and supply chain field, don’t miss your opportunity to gain exclusive technical and logistical insights from the likes of from Fusion Pharmaceuticals, Ratio Therapeutics, the IAEA, Telix Pharmaceuticals and many more.

With BMS-RayzeBio already forced to pause a phase III trial due to an actinium scarcity and AstraZeneca pouring $20M funding into new CDMO player Nucleus RadioPharma to further expand manufacturing capabilities – it is more crucial than ever to lead in supply chain and manufacturing of radiopharmaceuticals to safeguard and stay at the forefront of radiopharmaceutical innovation.

URLs:

Tickets: https://go.evvnt.com/2502188-2?pid=91 

Brochure: https://go.evvnt.com/2502188-3?pid=91 

Prices:

Drug Developer Full Package (Conference + Pre-Conference Workshop Day): USD 4097.00,

Drug Developer Conference Only: USD 2899.00,

Solution Provider Full Package (Conference + Pre-Conference Workshop Day): USD 4997.00,

Solution Provider Conference Only: USD 3699.00

Speakers: Angel Colina, Director - Cyclotron Engineering and Operations, Columbia University Irving Medical Center, Aruna Korde, Scientist, International Atomic Energy Agency, Brett Miller, Senior Director - Global Supply Chain, Telix Pharmaceuticals, Bryce Kanter, Senior Director - Commercial Development, Clarity Pharmaceuticals, Chris Pak, President and Chief Executing Officer, Molecular Targeting Technologies, Daniel Thorek, Associate Professor, Washington University School of Medicine in St. Louis, Erwin Bachmohr, Consultant, acting as Head of Procurement and Supply Chain, Aricium Pharmaceuticals, Gokhan Cakmak, Vice President - Supply Chain and Logistics, Fusion Pharmaceuticals, Kemp Dolliver, Director - Research and Senior Analyst, Brookline Capital Markets, Ken Baker, Senior Director - External Manufacturing, Fusion Pharmaceuticals, Matthias Friebe, Chief Technology Officer, Ratio Therapeutics, Matthias Friebe, Chief Technology Officer, Ratio Therapeutics, Michelle Hickey, Senior Vice President - Global Manufacturing, Telix Pharmaceuticals, Prab Takhar, Radiochemist, Region Ostergotland, Shankar Vallabhajosula, Vice President, Radiopharmaceutical Sciences, Convergent Therapeutics